Free of Complexing Proteins - Enough for Low Immunogenicity of Botulinum Neurotoxin Formulations? A Comparison of Excipients

被引：0

作者：

Martin, Michael U. ^{[1
]}

Frevert, Juergen ^{[2
]}

机构：

[1] Justus Liebig Univ Giessen, D-35390 Giessen, Germany

[2] Merz Pharmaceut GmbH, Frankfurt, Germany

来源：

TOXICON | 2024年 / 237卷

关键词：

BotulinumtoxinA; Coretox; DaxibotulintoxinA-Lanm; Excipients; Immunogenicity; IncobotulinumtoxinA;

D O I：

10.1016/j.toxicon.2024.107447

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：54 / 55

页数：2

共 50 条

[21] Efficacy of NT 201 (Xeomin®; Botulinum neurotoxin type A free from complexing proteins) in the treatment of patients with focal dystonia
Grafe, S.
Hanschmann, A.
JOURNAL OF NEURAL TRANSMISSION, 2010, 117 (10) : 1235 - 1235
[22] Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with blepharospasm
Grafe, S.
Hanschmann, A.
Jankovic, J.
Comella, C.
MOVEMENT DISORDERS, 2010, 25 (07) : S235 - S236
[23] Efficacy of NT 201 (botulinum neurotoxin type A, free from complexing proteins) in the treatment of patients with upper limb spasticity
Kanovsky, P.
Barnes, M. P.
Pulte, I.
Minnasch, P.
Grafe, S.
MOVEMENT DISORDERS, 2010, 25 (07) : S523 - S523
[24] Efficacy of NT 201 (Botulinum Neurotoxin Type A, Free from Complexing Proteins) in the Treatment of Patients with Upper Limb Spasticity
Kanovsky, Petr
Barnes, Michael
Pulte, Irena
Minnasch, Petra
Grafe, Susanne
NEUROLOGY, 2010, 74 (09) : A153 - A153
[25] Xeomin® is stable without refrigeration:: Complexing proteins are not required for stability of botulinum neurotoxin type A preparations
Grein, Swen
Mander, Gerd J.
Taylor, Harold V.
TOXICON, 2008, 51 : 13 - 13
[26] A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function
Dodd, SL
Rowell, BA
Vrabas, IS
Arrowsmith, RJ
Weatherill, PJ
EUROPEAN JOURNAL OF NEUROLOGY, 1998, 5 (02) : 181 - 186
[27] Efficacy and safety of NT 201, botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients
Grafe, S.
Comella, C.
Jankovic, J.
Truong, D.
Hanschmann, A.
MOVEMENT DISORDERS, 2009, 24 : S92 - S92
[28] Efficacy and safety of NT 201; botulinum neurotoxin type A free from complexing proteins) in treatment-naive cervical dystonia patients
Grafe, S.
Comella, C.
Jankovic, J.
Truong, D.
Hanschmann, A.
MOVEMENT DISORDERS, 2009, 24 : S92 - S93
[29] Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins
Oh, Hyun-Mi
Park, Joo Hyun
Song, Dae Heon
Chung, Myung Eun
TOXINS, 2016, 8 (01):
[30] Repeated injections of NT 201 (botulinum neurotoxin free from complexing proteins) in upper limb post-stroke spasticity patients
Kanovsky, P.
Sassin, I.
Comes, G.
Grafe, S.
Platz, T.
MOVEMENT DISORDERS, 2009, 24 : S452 - S453

← 1 2 3 4 5 →